Prohemostatic and Antithrombin Activities of Ankaferd Hemostat Are Linked to Fibrinogen Gamma Chain and Prothrombin by Functional Proteomic Analyses

Creative Commons License

ÖZEL DEMİRALP F. D., Igci N., Ayhan B., Egin Y., HAZNEDAROĞLU İ. C., Akar N.

CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, vol.18, no.6, pp.604-610, 2012 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 18 Issue: 6
  • Publication Date: 2012
  • Doi Number: 10.1177/1076029612436672
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.604-610
  • Keywords: Ankaferd, proteomics, fibrinogen gamma, prothrombin, hemostasis, CONTROLLED CLINICAL-TRIAL, BLOOD STOPPER, IN-VITRO, THROMBIN, BIOLOGY, PLASMA
  • Dokuz Eylül University Affiliated: No


Ankaferd blood stopper (ABS) is a novel topical hemostatic agent of plant origin registered for the management of external hemorrhages, in Turkey. The ABS-induced formation of the protein network with vital erythroid aggregation covers the whole physiological hemostatic process. The aim of this study is to assess prohemostatic and antithrombin effects of ABS on the basis of functional proteomic analyses performed in ABS-treated plasma and serum samples based on the previous hypotheses about ABS action. For this purpose, serum and plasma proteins were separated by 2-dimensional (2D) gel electrophoresis, and proteins were identified using reference plasma gel on Swiss-2DPAGE database. Our results indicated that fibrinogen gamma chain and prothrombin levels just initially decreased first and thereafter enhanced following the ABS exposure. Dual effects of ABS on those critical hemostatic molecules seem to be associated with prohemostatic and antithrombin activities of the hemostatic agent.